Rivastigmine Reduces Tobacco Craving in Alcohol-dependent Smokers

Abstract

Introduction: Although alcohol-dependent smokers represent an important group for applying smoking interventions, a sufficient pharmacotherapy has not been established in this high-risk group so far.

Methods: In order to examine the effect of the acetylcholinesterase inhibitor rivastigmine on tobacco dependence, we performed a 12-week, randomized, placebo-controlled trial. 26 alcohol-dependent smokers were randomized to rivastigmine 6 mg/day (n=14) or placebo (n=12). Assessments on addictive behavior included carbon monoxide (CO), severity of tobacco dependence (FTND), daily smoked cigarettes (diaries), and craving for tobacco (QSU) and alcohol (AUQ).

Results: ANOVA revealed a significant treatment-by-time interaction for tobacco consumption and tobacco craving (each p<0.0001). The rivastigmine group showed a decrease in daily smoked cigarettes (−30%), in exhaled carbon monoxide (−32%) and in tobacco craving (−18%) whereas controls did not show significant changes. ANCOVA revealed rivastigmine effects to be more prominent in smokers suffering from more severe tobacco dependence. None of the patients developed an alcohol relapse or an increase in alcohol craving.

Discussion: Our preliminary data indicate an effect of rivastigmine on tobacco craving and consumption. This pilot study encourages further investigation of acetylcholinesterase-inhibitors as a promising treatment approach regarding tobacco dependence.

References

• 1 Assion HJ, Jungck C. Off-label prescribing in a German psychiatric hospital.  Pharmacopsychiatry. 2007;  40 30-36
• 2 Bobo JK, MacIlvain HE, Lando HA. et al . Effect of smoking cessation counseling on recovery from alcoholism: findings from a randomized community intervention trial.  Addiction. 1998;  93 877-887
• 3 Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics.  Alcohol Clin Exp Res. 1995;  19 600-606
• 4 Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse.  Neuron. 1996;  16 905-908
• 5 Diaz FJ, Santoro V, Spina E. et al . Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables.  Pharmacopsychiatry. 2008;  41 81-91
• 6 Diehl A, Mann K. Pharmacological relapse prevention in alcohol and tobacco dependence.  Internist (Berl). 2007;  48 79-88
• 7 Diehl A, Nakovics H, Croissant B. et al . Psychiatric liaison service in general hospitals: improvement in physicians' detection rates of alcohol use disorders.  Psychosomatics. 2008;  , [in press]
• 8 Diehl A, Nakovics H, Croissant B. et al . Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial.  Int J Clin Pharmacol Ther. 2006;  44 614-622
• 9 Diehl A, Scherbaum N. Nicotine dependence as comorbidity of alcohol dependence – epidemiology, etiology and therapy.  Fortschr Neurol Psychiatr. 2008;  76 14-18
• 10 Ferguson JA, Patten CA, Schroeder DR. et al . Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence.  Addict Behav. 2003;  28 1203-1218
• 11 Fiore MC, Bailey WC, Cohen SJ. et al . Treating tobacco use and dependence.  Clinical Practice Guideline. U.S. Department of Health and Human Services, Public Health Service. 2000; 
• 12 Fric M, Pfuhlmann B, Laux G. et al . The influence of smoking on the serum level of duloxetine.  Pharmacopsychiatry. 2008;  41 151-155
• 13 Gershon Grand RB, Hwang S, Han J. et al . Short-term naturalistic treatment outcomes in cigarette smokers with substance abuse and/or mental illness.  J Clin Psychiatry. 2007;  68 892-898
• 14 Heatherton TF, Kozlowski LT, Frecker RC. et al . The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire.  Br J Addict. 1991;  86 1119-1127
• 15 Hertling I, Ramskogler K, Dvorak A. et al . Craving and other characteristics of the comorbidity of alcohol and nicotine dependence.  Eur Psychiatry. 2005;  20 442-450
• 16 Hughes JR. Clinical implications of the association between smoking and alcoholism. In: Fertig J, Fuller R, eds. Alcohol and Tobacco: From Basic Science to Policy. Rockville, MD: National Institute on Alcoholism and Alcohol Abuse 1996: 171-185
• 17 Hughes JR, Carpenter MJ. The feasibility of smoking reduction: an update.  Addiction. 2005;  100 1074-1089
• 18 Hughes JR, Novy P, Hatsukami DK. et al . Efficacy of nicotine patch in smokers with a history of alcoholism.  Alcohol Clin Exp Res. 2003;  27 946-954
• 19 Hughes JR, Rose GL, Callas PW. Nicotine is more reinforcing in smokers with a past history of alcoholism than in smokers without this history.  Alcohol Clin Exp Res. 2000;  24 1633-1638
• 20 Hurt RD, Eberman KM, Croghan IT. et al . Nicotine dependence treatment during inpatient treatment for other addictions: a prospective intervention trial.  Alcohol Clin Exp Res. 1994;  18 867-872
• 21 Hurt RD, Offord KP, Croghan IT. et al . Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort.  JAMA. 1996;  275 1097-1103
• 22 Hurt RD, Patten CA. Treatment of tobacco dependence in alcoholics.  Recent Dev Alcohol. 2003;  16 335-359
• 23 Jimenez-Ruiz C, Solano S, Viteri SA. et al . Harm reduction – a treatment approach for resistant smokers with tobacco-related symptoms.  Respiration. 2002;  69 452-455
• 24 Joseph AM, Willenbring ML, Nugent SM. et al . A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment.  J Stud Alcohol. 2004;  65 681-691
• 25 Kalman D, Hayes K, Colby SM. et al . Concurrent versus delayed smoking cessation treatment for persons in early alcohol recovery.  A pilot study. J Subst Abuse Treat. 2001;  20 233-238
• 26 Kandel D, Chen K, Warner LA. et al . Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population.  Drug Alcohol Depend. 1997;  44 11-29
• 27 Kreek MJ, Nielsen DA, Butelman ER. et al . Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction.  Nat Neurosci. 2005;  8 1450-1457
• 28 McIlvain HE, Bobo JK, Leed-Kelly A. et al . Practical steps to smoking cessation for recovering alcoholics.  Am Fam Physician. 1998;  57 1869-1882
• 29 Olbrich R, Trager S, Nikitopoulos J. et al . Smoking reduction during inpatient alcohol detoxification.  Fortschr Neurol Psychiatr. 2008;  76 272-277
• 30 Pakkanen JS, Jokitalo E, Tuominen RK. Up-regulation of beta2 and alpha7 subunit containing nicotinic acetylcholine receptors in mouse striatum at cellular level.  Eur J Neurosci. 2005;  21 2681-2691
• 31 Prochaska JO, DiClemente CC. Stages of change in the modification of problem behaviors. In: Hersen M, Eisler RM, Miller PM, eds. Progress in behavior modifications. Sycamore: Sycamore Press 1992
• 32 Schroter M, Collins SE, Frittrang T. et al . Randomized controlled trial of relapse prevention and a standard behavioral intervention with adult smokers.  Addict Behav. 2005; 
• 33 Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation.  J Abnorm Psychol. 1982;  91 199-209
• 34 Tiffany ST, Drobes DJ. The development and initial validation of a questionnaire on smoking urges.  Br J Addict. 1991;  86 1467-1476
• 35 Toneatto A, Sobell LC, Sobell MB. et al . Effect of cigarette smoking on alcohol treatment outcome.  J Subst Abuse. 1995;  7 245-252
• 36 Wennike P, Danielsson T, Landfeldt B. et al . Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up.  Addiction. 2003;  98 1395-1402

Correspondence